Trial site
Ciudad Autónoma Buenos Aires
Ciudad Autónoma Buenos Aires, 1125, ArgentinaNot linked to an institution yet
The trials here
What the 8 trials at this site are about, from their registry records.
- Phase
- Phase 37 trials
- Phase 21 trial
- Status
- Recruiting5 trials
- Active, not recruiting2 trials
- Not yet recruiting1 trial
- Lead sponsor
- AstraZeneca7 trials
- Arrowhead Pharmaceuticals1 trial
Running trials
Not yet recruiting
A Study to Investigate the Efficacy and Safety of Dato-DXd-based Combinations in Participants With TROP2 NMR+ NSCLC
NCT07941609· Phase 2· AstraZeneca· Source
Recruiting
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
NCT07044336· Phase 3· AstraZeneca· Source
Recruiting
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
NCT06880770· Phase 3· Arrowhead Pharmaceuticals· Source
Contact: Medical Monitor
Recruiting
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
NCT06764875· Phase 3· AstraZeneca· Source
Recruiting
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
NCT06380751· Phase 3· AstraZeneca· Source
Recruiting
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
NCT06103864· Phase 3· AstraZeneca· Source
Contact: AstraZeneca Breast Cancer Study Locator Service
Active, not recruiting
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
NCT05374512· Phase 3· AstraZeneca· Source
Active, not recruiting
Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC
NCT05043090· Phase 3· AstraZeneca· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error